Originally published as JCO Early Release 10.1200/JCO.2006.09.9994 on May 21 2007

This Article Full Text Full Text (PDF) Erratum (v25,p5048) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coudert, B. P. Articles by Namer, M. Search for Related Content PubMed PubMed Citation Articles by Coudert, B. P. Articles by Namer, M. Social Bookmarking                            What's this?

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

Bruno P. Coudert, Remy Largillier, Laurent Arnould, Philippe Chollet, Mario Campone, David Coeffic, Frank Priou, Joseph Gligorov, Xavier Martin, Véronique Trillet-Lenoir, Béatrice Weber, Jean Pierre Bleuse, Berangère Vasseur, Daniel Serin, Moïse Namer

From the Departments of Oncology and Pathology, CAC G.F. Leclerc and IFR 100, Dijon; Oncology, CAC A. Lacassagne, Nice; Oncology, CAC J. Perrin, Clermont Ferrand; Oncology, CAC R. Gauducheau, Nantes; Oncology, Clinique du Mail, Grenoble; Oncology, CH Les Oudairies, La Roche sur Yon; Oncology, Cancer Est, APHP Tenon; Oncology, Sanofi-aventis, Paris; Oncology, Clinique St Marie, Chalon sur Saone; Université Lyon 1, EA3738 et CH Lyon Sud, Lyon; Oncology, CAC A Vautrin, Nancy; Oncology, Roche, Neuilly; and Oncology, Institut St Catherine, Avignon, France

Address reprint requests to Bruno P. Coudert, MD, Centre GF Leclerc, 1 rue du Pr Marion, 21000 Dijon, France; e-mail: bcoudert{at}dijon.fnclcc.fr

Purpose Trastuzumab plus chemotherapy has become the standard of care for human epidermal growth factor receptor-2 (HER-2) –positive breast cancer. Trastuzumab-based preoperative systemic therapy (PST; neoadjuvant therapy) also appears promising, warranting further investigation.

Patients and Methods Patients with HER-2-positive, stage II/III, noninflammatory, operable breast cancer requiring a mastectomy (but who wanted to conserve the breast) received trastuzumab 4 mg/kg (day 1), followed by 2 mg/kg weekly, plus docetaxel 75 mg/m² every 3 weeks, and carboplatin (area under curve, 6) for six cycles before surgery. The primary end point was pathologic complete response (pCR) rate, determined from surgical specimens.

Results Seventy patients were enrolled. Most patients had clinical T2/T3 tumors (100%) or clinical N1/2 nodes (53%). Sixty-seven patients (96%) completed six cycles of therapy, one patient withdrew due to progressive disease, and two patients withdrew for toxicity. A complete or partial objective clinical response occurred in 95% of patients (85% and 10%, respectively). Surgery was breast conservative in 45 (64%) of 70 patients. In an intent-to-treat analysis, tumor and nodal pCR were seen in 27 (39%) of 70 patients. Centralized retrospective analysis of HER-2 status demonstrated a 43% pCR rate in the 24 of 56 confirmed HER-2-overexpressing (3+) and/or fluorescence in situ hybridization–positive tumors. Treatment was generally well tolerated. Grade 3/4 neutropenia and febrile neutropenia were uncommon (2%). Two patients withdrew prematurely due to a transient, asymptomatic decrease in left ventricular ejection fraction. No symptomatic cardiac dysfunction occurred.

Conclusion PST with trastuzumab plus docetaxel and carboplatin achieved promising efficacy, with a good pCR rate and favorable tolerability in stage II or III HER-2-positive breast cancer.

published online ahead of print at www.jco.org on May 21, 2007.

Presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Gong, W. Sweet, Y.-J. Duh, L. Greenfield, Y. Fang, J. Zhao, E. Tarco, W. F. Symmans, J. Isola, and N. Sneige Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations Am J Clin Pathol, April 1, 2009; 131(4): 490 - 497. [Abstract] [Full Text] [PDF]

				J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]

				J. HORIGUCHI, T. OYAMA, Y. KOIBUCHI, T. YOKOE, D. TAKATA, F. IKEDA, H. NAGAOKA, N. ROKUTANDA, R. NAGAOKA, Y. ISHIKAWA, et al. Neoadjuvant Weekly Paclitaxel with and without Trastuzumab in Locally Advanced or Metastatic Breast Cancer Anticancer Res, February 1, 2009; 29(2): 517 - 524. [Abstract] [Full Text] [PDF]

				M. Martin, F. J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J. A. Garcia-Saenz, A. Marquez, P. Sengupta, and J. Zamorano Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations Oncologist, January 1, 2009; 14(1): 1 - 11. [Abstract] [Full Text] [PDF]

				S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff Locally Advanced and Inflammatory Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 786 - 790. [Full Text] [PDF]

				L. Arnould, P. Arveux, J. Couturier, M. Gelly-Marty, C. Loustalot, F. Ettore, C. Sagan, M. Antoine, F. Penault-Llorca, B. Vasseur, et al. Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification Clin. Cancer Res., November 1, 2007; 13(21): 6404 - 6409. [Abstract] [Full Text] [PDF]